A settled NICE algorithm: stiripentol backbone, then cannabidiol, then fenfluramine — both NHS-commissioned with confidential PAS.
NHS England Highly Specialised Services commission Dravet Syndrome management at 25 designated paediatric neurology centres, covering an estimated 400-500 UK patients. NICE has recommended two agents onto the standard pathway: cannabidiol (Epidiolex, NICE TA614, 2019) and fenfluramine (Fintepla, NICE TA808, 2022), both with confidential Patient Access Schemes. Stiripentol (Diacomit), the oldest Dravet-specific agent, has never gone through a dedicated NICE technology appraisal; it is covered under NICE clinical guideline CG137 and still anchors the backbone regimen alongside valproate and clobazam in many centres.
The NHS treatment algorithm is now fixed: stiripentol-based backbone first, cannabidiol added if seizures persist, fenfluramine added if cannabidiol response is inadequate. NHS annual cost per patient is approximately £25,000-35,000 on cannabidiol and £40,000-60,000 on fenfluramine (both post-PAS, the latter including mandatory cardiac monitoring under the Fintepla Cardiac Monitoring Scheme). A new therapy entering this space faces a structural barrier: it must demonstrate superiority or a materially better tolerability profile to dislodge an already NICE-recommended, PAS-priced two-drug sequence — not simply achieve its own positive appraisal.
NHS-commissioned Dravet Syndrome agents — UK, 2026
| Drug (Brand / INN) | Mechanism | Company | UK Regulatory / NICE Status | Key Trial Result | NHS Commissioning |
|---|---|---|---|---|---|
| Epidiolex (cannabidiol) | Oral plant-derived cannabidiol | Jazz Pharmaceuticals | MHRA approved; NICE TA614 (2019) recommended | NICE TA614 recommended for Dravet and Lennox-Gastaut Syndrome (GWPCARE1-4 trials) | NHS HSS commissioned; ~25 paediatric neurology HSS centres; leading UK Dravet standard of care |
| Fintepla (fenfluramine) | Low-dose serotonin-releasing agent | UCB | MHRA approved; NICE TA808 (2022) recommended | NICE TA808 recommended for patients ≥2 years inadequately controlled by ≥2 ASMs (STUDIO 1 & 2) | NHS HSS commissioned; cardiac monitoring via FCMS; used after cannabidiol inadequate response |
| Diacomit (stiripentol) | GABA-A positive allosteric modulator — adjunct | Biocodex | MHRA approved; covered under NICE CG137, no dedicated technology appraisal | Adjunct use with valproate + clobazam supported by STICLO trial data; never formally cost-effectiveness reviewed by NICE | NHS commissioned; oldest Dravet-specific agent; still used in backbone regimens at some centres |
Sources: MHRA product licences; NICE TA614 Cannabidiol for Dravet and Lennox-Gastaut Syndrome (2019); NICE TA808 Fenfluramine for Dravet Syndrome (2022); NICE CG137 The epilepsies: diagnosis and management (stiripentol has no dedicated technology appraisal); NHS England Highly Specialised Services commissioning documents.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NICE TA614 and TA808 evidence thresholds
- the seizure-reduction and tolerability bar a new agent must clear to be considered for algorithm placement
Delivers
- HSS commissioning criteria
- the referral pathway into designated centres
- the practical barrier non-designated hospitals face in prescribing
Delivers
- SCN1A panel turnaround and confirmation rates
- genomic testing infrastructure relevant to biomarker-defined trial design and patient identification
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why NHS England commissions Dravet Syndrome management at 25 designated paediatric neurology centres for an estimated 400-500 UK patients
- How stiripentol, cannabidiol and fenfluramine together define the current three-agent UK competitive map
- Full profiles of cannabidiol (Epidiolex, NICE TA614), fenfluramine (Fintepla, NICE TA808) and stiripentol (Diacomit, NICE CG137)
- Mechanism, sponsor, regulatory status and trial evidence for all three agents, from Jazz Pharmaceuticals through UCB and Biocodex
- Why the NHS treatment algorithm is now fixed: stiripentol-based backbone first, cannabidiol added next, fenfluramine added if response is inadequate
- How post-PAS annual costs of roughly £25,000-35,000 on cannabidiol and £40,000-60,000 on fenfluramine set the price a new entrant must beat
- Why a 75% SCN1A molecular confirmation rate via the NHS Genomics Medicine Service shapes how clinically diagnosed patients reach treatment
- How referral into one of the 25 designated Highly Specialised Services centres gates access to the full treatment sequence
- How roughly 50 consultants nationally across the 25 HSS centres concentrate Dravet Syndrome prescribing decisions
- Why stiripentol's continued use in backbone regimens, despite lacking a dedicated NICE technology appraisal, reflects entrenched prescriber habit
- Why a new therapy must demonstrate superiority or materially better tolerability to dislodge the already NICE-recommended, PAS-priced two-drug sequence
- How the Fintepla Cardiac Monitoring Scheme's mandatory monitoring burden creates a tolerability bar any new entrant must clear or beat
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (MHRA, NICE), peer-reviewed literature, and NHS commissioning documentation — not secondary summaries. Findings are independently verified before inclusion.
Dravet Syndrome UK CI sources: NICE TA614 (cannabidiol), NICE TA808 (fenfluramine), NICE CG137 (stiripentol — no dedicated technology appraisal exists), NHS England Highly Specialised Services specification for Dravet Syndrome, British Paediatric Neurology Association reporting, NHS Genomics Medicine Service epilepsy gene panel specifications, and Genomics England 100,000 Genomes Project Dravet cohort data.
- MHRA approval status verified against current product licence information
- NICE technology appraisal recommendations verified against published TA614 and TA808 documents; stiripentol's CG137 clinical-guideline basis (no dedicated technology appraisal) confirmed directly on NICE.org.uk
- NHS HSS commissioning structure verified against NHS England service specification documents
- Clinical trial results verified against the primary trial evidence cited in each NICE appraisal (GWPCARE1-4, STUDIO 1&2, STICLO)
Frequently asked questions
Commission this brief
AXLRx delivers Dravet Syndrome competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams targeting the UK NHS pathway. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.